WO2008093848A1 - ホスファチジルコリンを含有する炎症マーカー低減組成物 - Google Patents
ホスファチジルコリンを含有する炎症マーカー低減組成物 Download PDFInfo
- Publication number
- WO2008093848A1 WO2008093848A1 PCT/JP2008/051680 JP2008051680W WO2008093848A1 WO 2008093848 A1 WO2008093848 A1 WO 2008093848A1 JP 2008051680 W JP2008051680 W JP 2008051680W WO 2008093848 A1 WO2008093848 A1 WO 2008093848A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phosphatidylcholine
- composition
- inflammation marker
- liposome
- disclosed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
Abstract
炎症マーカーの増大により引き起こされる身体機能の不全を予防又は改善し、メタボリックシンドロームや疾患リスクの発生を低減させ、健康を維持又は増進する経口又は口腔用の医薬品、機能性食品および口腔用組成物を提供する。
大豆由来のホスファチジルコリンを、好ましくは1位又は2位のいずれか1つ以上に不飽和脂肪酸、特にリノール酸又はリノレン酸が結合したホスファチジルコリンを使用してカプセル剤、錠剤、液剤に配合する。ホスファチジルコリンは好ましくはリポソームの形態にする。さらにω3系不飽和脂肪酸をリポソーム又はリピッドマイクロスフェアに内包する。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008556205A JPWO2008093848A1 (ja) | 2007-02-02 | 2008-02-01 | ホスファチジルコリンを含有する炎症マーカー低減組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007024241 | 2007-02-02 | ||
JP2007-024241 | 2007-02-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008093848A1 true WO2008093848A1 (ja) | 2008-08-07 |
Family
ID=39674151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/051680 WO2008093848A1 (ja) | 2007-02-02 | 2008-02-01 | ホスファチジルコリンを含有する炎症マーカー低減組成物 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2008093848A1 (ja) |
WO (1) | WO2008093848A1 (ja) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010100653A2 (en) | 2009-02-02 | 2010-09-10 | Laila Nutraceuticals | Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome |
JP2012031135A (ja) * | 2010-06-29 | 2012-02-16 | Kao Corp | フルクトース誘導性疾患の予防又は改善剤 |
WO2012102364A1 (ja) * | 2011-01-27 | 2012-08-02 | サンスター株式会社 | 多価不飽和脂肪酸含有組成物 |
US8703215B2 (en) | 2009-08-04 | 2014-04-22 | Laila Nutraceuticals | Agents from Ficus hispida for the amelioration of metabolic syndrome and related diseases |
JP2015000853A (ja) * | 2013-06-14 | 2015-01-05 | 日油株式会社 | 歯肉炎予防剤 |
CN104288464A (zh) * | 2014-10-17 | 2015-01-21 | 李晓丽 | 一种治疗心脑血管疾病的中药 |
JP2015174860A (ja) * | 2014-03-18 | 2015-10-05 | サンスター株式会社 | オーラルケア組成物 |
CN105288100A (zh) * | 2014-07-30 | 2016-02-03 | 陈立云 | 一种专治阻塞肺气肿的中药组合物 |
US9345732B2 (en) | 2009-11-19 | 2016-05-24 | Laila Nutraceuticals | Agents derived from Holoptelea integrifolia and their compositions for the control of metabolic syndrome and associated diseases |
WO2016185816A1 (ja) * | 2015-05-18 | 2016-11-24 | 不二製油グループ本社株式会社 | IL-1β産生抑制作用を有する食品添加用組成物 |
JP2017527614A (ja) * | 2014-09-02 | 2017-09-21 | ブピンダー シン | 重水素化又は非重水素化分子及び医薬製剤 |
JP2018115179A (ja) * | 2018-03-16 | 2018-07-26 | サンスター株式会社 | オーラルケア組成物 |
JP2019531309A (ja) * | 2016-10-19 | 2019-10-31 | サインパス ファルマ, インク.Signpath Pharma, Inc. | チャネル病を引き起こす薬物に対するdmpc、dmpg、dmpc/dmpg、lysopg及びlysopcの防御効果 |
JP2021500318A (ja) * | 2017-10-19 | 2021-01-07 | サインパス ファルマ, インク.Signpath Pharma, Inc. | チャネル病を引き起こす薬物に対するdmpc、dmpg、dmpc/dmpg、lysopg及びlysopcの防御効果 |
CN113575824A (zh) * | 2021-08-25 | 2021-11-02 | 上海英库商务咨询有限公司 | 用于预防ii型糖尿病人群代谢综合征的固体饮料 |
JP2023024673A (ja) * | 2019-01-21 | 2023-02-16 | 和三郎 佐藤 | 神経機能再生促進剤 |
US11806401B2 (en) | 2016-04-27 | 2023-11-07 | Signpath Pharma, Inc. | Prevention of drug-induced atrio-ventricular block |
US12004868B2 (en) | 2011-06-03 | 2024-06-11 | Signpath Pharma Inc. | Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61112020A (ja) * | 1984-10-10 | 1986-05-30 | エルヴイラ ピストレツシ− | 抗血栓性並びに抗動脈硬化性高活性を有する薬剤的又は栄養的組成物 |
JPS62116516A (ja) * | 1985-11-18 | 1987-05-28 | Nippon Oil & Fats Co Ltd | レシチン組成物及びその製造法 |
JPH04169525A (ja) * | 1990-11-01 | 1992-06-17 | Nissei Marine Kogyo Kk | 血清脂質改善機能を有する組成物 |
JPH09176005A (ja) * | 1995-12-21 | 1997-07-08 | Sigma Tau Ind Farmaceut Riunite Spa | オメガ−3系のポリ不飽和脂肪酸を併用するl−カルニチンまたはアルカノイル l−カルニチン含有医薬組成物 |
JP2001002565A (ja) * | 1999-06-08 | 2001-01-09 | Crinos Ind Farmacobiolog Spa | カチオン性リポソームとポリデオキシリボヌクレオチドとの複合体 |
WO2003022288A1 (fr) * | 2001-09-07 | 2003-03-20 | Meiji Dairies Corporation | Compositions nutritionnelles permettant de reguler le niveau de glucose sanguin |
JP2006298913A (ja) * | 2005-03-25 | 2006-11-02 | Lion Corp | 歯周組織破壊の抑制・改善剤及びスクリーニング方法 |
-
2008
- 2008-02-01 JP JP2008556205A patent/JPWO2008093848A1/ja active Pending
- 2008-02-01 WO PCT/JP2008/051680 patent/WO2008093848A1/ja active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61112020A (ja) * | 1984-10-10 | 1986-05-30 | エルヴイラ ピストレツシ− | 抗血栓性並びに抗動脈硬化性高活性を有する薬剤的又は栄養的組成物 |
JPS62116516A (ja) * | 1985-11-18 | 1987-05-28 | Nippon Oil & Fats Co Ltd | レシチン組成物及びその製造法 |
JPH04169525A (ja) * | 1990-11-01 | 1992-06-17 | Nissei Marine Kogyo Kk | 血清脂質改善機能を有する組成物 |
JPH09176005A (ja) * | 1995-12-21 | 1997-07-08 | Sigma Tau Ind Farmaceut Riunite Spa | オメガ−3系のポリ不飽和脂肪酸を併用するl−カルニチンまたはアルカノイル l−カルニチン含有医薬組成物 |
JP2001002565A (ja) * | 1999-06-08 | 2001-01-09 | Crinos Ind Farmacobiolog Spa | カチオン性リポソームとポリデオキシリボヌクレオチドとの複合体 |
WO2003022288A1 (fr) * | 2001-09-07 | 2003-03-20 | Meiji Dairies Corporation | Compositions nutritionnelles permettant de reguler le niveau de glucose sanguin |
JP2006298913A (ja) * | 2005-03-25 | 2006-11-02 | Lion Corp | 歯周組織破壊の抑制・改善剤及びスクリーニング方法 |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010100653A2 (en) | 2009-02-02 | 2010-09-10 | Laila Nutraceuticals | Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome |
US8703215B2 (en) | 2009-08-04 | 2014-04-22 | Laila Nutraceuticals | Agents from Ficus hispida for the amelioration of metabolic syndrome and related diseases |
US9345732B2 (en) | 2009-11-19 | 2016-05-24 | Laila Nutraceuticals | Agents derived from Holoptelea integrifolia and their compositions for the control of metabolic syndrome and associated diseases |
JP2012031135A (ja) * | 2010-06-29 | 2012-02-16 | Kao Corp | フルクトース誘導性疾患の予防又は改善剤 |
JPWO2012102364A1 (ja) * | 2011-01-27 | 2014-06-30 | サンスター株式会社 | 多価不飽和脂肪酸含有組成物 |
US8940312B2 (en) | 2011-01-27 | 2015-01-27 | Sunstar Inc. | Composition containing polyunsaturated fatty acid |
WO2012102364A1 (ja) * | 2011-01-27 | 2012-08-02 | サンスター株式会社 | 多価不飽和脂肪酸含有組成物 |
JP6137836B2 (ja) * | 2011-01-27 | 2017-05-31 | サンスター株式会社 | 多価不飽和脂肪酸含有組成物 |
JP2017114895A (ja) * | 2011-01-27 | 2017-06-29 | サンスター株式会社 | 多価不飽和脂肪酸含有組成物 |
KR101771063B1 (ko) * | 2011-01-27 | 2017-08-24 | 선스타 가부시키가이샤 | 다가 불포화 지방산 함유 조성물 |
US12004868B2 (en) | 2011-06-03 | 2024-06-11 | Signpath Pharma Inc. | Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel |
JP2015000853A (ja) * | 2013-06-14 | 2015-01-05 | 日油株式会社 | 歯肉炎予防剤 |
JP2015174860A (ja) * | 2014-03-18 | 2015-10-05 | サンスター株式会社 | オーラルケア組成物 |
CN105288100A (zh) * | 2014-07-30 | 2016-02-03 | 陈立云 | 一种专治阻塞肺气肿的中药组合物 |
JP2017527614A (ja) * | 2014-09-02 | 2017-09-21 | ブピンダー シン | 重水素化又は非重水素化分子及び医薬製剤 |
CN104288464A (zh) * | 2014-10-17 | 2015-01-21 | 李晓丽 | 一种治疗心脑血管疾病的中药 |
JP6103143B1 (ja) * | 2015-05-18 | 2017-03-29 | 不二製油株式会社 | IL−1β産生抑制作用を有する食品添加用組成物 |
WO2016185816A1 (ja) * | 2015-05-18 | 2016-11-24 | 不二製油グループ本社株式会社 | IL-1β産生抑制作用を有する食品添加用組成物 |
US11806401B2 (en) | 2016-04-27 | 2023-11-07 | Signpath Pharma, Inc. | Prevention of drug-induced atrio-ventricular block |
JP2019531309A (ja) * | 2016-10-19 | 2019-10-31 | サインパス ファルマ, インク.Signpath Pharma, Inc. | チャネル病を引き起こす薬物に対するdmpc、dmpg、dmpc/dmpg、lysopg及びlysopcの防御効果 |
JP2021500318A (ja) * | 2017-10-19 | 2021-01-07 | サインパス ファルマ, インク.Signpath Pharma, Inc. | チャネル病を引き起こす薬物に対するdmpc、dmpg、dmpc/dmpg、lysopg及びlysopcの防御効果 |
JP2018115179A (ja) * | 2018-03-16 | 2018-07-26 | サンスター株式会社 | オーラルケア組成物 |
JP2023024673A (ja) * | 2019-01-21 | 2023-02-16 | 和三郎 佐藤 | 神経機能再生促進剤 |
CN113575824A (zh) * | 2021-08-25 | 2021-11-02 | 上海英库商务咨询有限公司 | 用于预防ii型糖尿病人群代谢综合征的固体饮料 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2008093848A1 (ja) | 2010-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008093848A1 (ja) | ホスファチジルコリンを含有する炎症マーカー低減組成物 | |
WO2011060945A3 (en) | Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases | |
WO2014005013A3 (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
WO2012091523A8 (en) | Carrier for negatively charged drugs comprising a cationic lipid and a preparation method thereof | |
SG10201400685SA (en) | Use Of Eicosapentaenoic Acid Ethyl Ester For Treating Hypertriglyceridemia | |
WO2011018501A3 (en) | Composition including an unsaponifiable fraction | |
JP2015503593A5 (ja) | ||
WO2010032140A3 (en) | Pharmaceutical compositions and related methods of delivery | |
WO2009022821A3 (en) | Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same | |
WO2006108692A3 (en) | Dosage form for oral administration of a vitamin | |
WO2011101866A3 (en) | Gastric retention formulation containing baclofen | |
HRP20240115T1 (hr) | Povećavanje bioraspoloživosti lijeka u terapiji naltreksonom | |
IL195931A0 (en) | Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and methods for its production | |
WO2007122635A3 (en) | Controlled release formulation comprising anti-epileptic drugs | |
MX2009012782A (es) | Formulaciones para administracion oral de agentes terapeuticos y metodos relacionados. | |
WO2011060944A3 (en) | Active pharmaceutical ingredient capsules and polyunsaturated fatty acid esters | |
WO2010127205A3 (en) | Fixed dose drug combination formulations | |
IN2014CN03214A (ja) | ||
EP2196463A4 (en) | PREPARATION OF 5,6-DIMETHYLXANTHONE-4-ACETIC ACID, DERIVATIVES DERIVATED THEREOF AND PHARMACEUTICAL FORMULATIONS THEREOF | |
RS52735B (en) | APPLICATION OF A COMBINATION CONTAINING L-CARNITINE OR ALKANOIL L-CARNITINE, OIL-SOLUBLE OIL-BENZOQUINON AND OMEGA-3-POLYESATURATED FATTY ACID FOR PREPARATION OF NUTRITION OR MEDICINAL PRODUCTS | |
WO2011143271A3 (en) | Therapeutic liposomes and methods for producing and using the same | |
WO2012053758A3 (ko) | 실로스타졸을 유효성분으로 함유하는 알코올성 간질환 치료 또는 예방용 약학조성물 | |
WO2013162298A8 (ko) | 신규한 베타 알라닌 유도체, 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 약제학적 조성물 | |
de la Lastra | Commentary on'Resveratrol commonly displays hormesis: Occurrence and biomedical significance'by Calabrese et al | |
EP1949900A3 (en) | Controlled release solid formulation for oral administration as single dose sachet and method of preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08710712 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008556205 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08710712 Country of ref document: EP Kind code of ref document: A1 |